NFA
SNDX icon

Nationwide Fund Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Nationwide Fund Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,962
Closed -$58K – 1788
2017
Q3 		$58K Hold
4,962
– – ﹤0.01% 3024
2017
Q2 		$69K Buy
4,962
+2,112
+74% +$24.1K ﹤0.01% 3015
2017
Q1 		$39K Hold
2,850
– – ﹤0.01% 3021
2016
Q4 		$20K Hold
2,850
– – ﹤0.01% 3085
2016
Q3 		$43K Hold
2,850
– – ﹤0.01% 3065
2016
Q2 		$28K Buy
+2,850
New +$39.1K ﹤0.01% 3128

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nationwide Fund Advisors's SNDX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2017, closing a stake of 4,962 shares — an estimated $58K sold.

Nationwide Fund Advisors first reported a position in SNDX in Q2 2016 and held it in 6 quarters. The position peaked at $69K in Q2 2017. 80 funds tracked by Wall St. Rank hold SNDX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 4,962 Syndax Pharmaceuticals shares in Q4 2017, an estimated $58K.
  • Nationwide Fund Advisors first reported a position in Syndax Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Nationwide Fund Advisors's Syndax Pharmaceuticals position peaked at $69K in Q2 2017.
  • 80 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.